OmniScience, a trailblazing leader for data science in the life sciences, is pleased to announce the appointment of Dr. Robyn Cardwell as the company’s new Chief Growth Officer. This strategic addition to OmniScience's leadership team represents a significant milestone in the company’s journey, offering promising opportunities for both customers and investors.

In the capacity of Chief Growth Officer, Dr. Cardwell will play a pivotal role in OmniScience's strategic vision, with a mission to drive groundbreaking data science solutions for life sciences clients. With a wealth of experience and a passion for innovation, Dr. Cardwell is poised to lead OmniScience into a new era of discovery and success.

Dr. Cardwell brings an impressive track record of achievements. She most recently served as the global business manager of ABB Robotics’ Life Sciences division, and was instrumental in bringing new technologies and platforms to market at Genomic Health (now Exact Sciences), Natera and Enthought. Dr. Cardwell has extensive expertise in precision medicine, genomics, laboratory automation and machine learning-driven scientific software development through various roles in sales, operations, product launch, customer success and partnership development. Her academic background includes a PhD in Biomedical Engineering from Virginia Tech & Wake Forest University. Dr. Cardwell’s deep industry insights and ability to harness cutting-edge technologies to advance life sciences align seamlessly with OmniScience's commitment to delivering transformative solutions.

OmniScience's CEO, Angela Holmes, emphasized the significance of this appointment for OmniScience, stating, "I am delighted to welcome Robyn to the team. Her appointment to our leadership team marks a pivotal moment in our company's evolution, as we embark on an exciting phase of expansion. Dr. Cardwell's impressive track record of innovation in life sciences makes her the ideal addition to our team. I look forward to the collaboration and success that lie ahead with her on board."